124 related articles for article (PubMed ID: 11049996)
1. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.
Treon SP; Maimonis P; Bua D; Young G; Raje N; Mollick J; Chauhan D; Tai YT; Hideshima T; Shima Y; Hilgers J; von Mensdorff-Pouilly S; Belch AR; Pilarski LM; Anderson KC
Blood; 2000 Nov; 96(9):3147-53. PubMed ID: 11049996
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MUC1 and EGP40 in bone marrow and peripheral blood as a marker for occult breast cancer.
Zhong XY; Kaul S; Bastert G
Arch Gynecol Obstet; 2001 Jan; 264(4):177-81. PubMed ID: 11205703
[TBL] [Abstract][Full Text] [Related]
3. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma.
Baldus SE; Palmen C; Thiele J
Histol Histopathol; 2007 Aug; 22(8):889-93. PubMed ID: 17503346
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
Noto H; Takahashi T; Makiguchi Y; Hayashi T; Hinoda Y; Imai K
Int Immunol; 1997 May; 9(5):791-8. PubMed ID: 9184925
[TBL] [Abstract][Full Text] [Related]
5. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
6. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.
Choi C; Witzens M; Bucur M; Feuerer M; Sommerfeldt N; Trojan A; Ho A; Schirrmacher V; Goldschmidt H; Beckhove P
Blood; 2005 Mar; 105(5):2132-4. PubMed ID: 15561890
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
[TBL] [Abstract][Full Text] [Related]
8. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
9. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
10. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
11. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
12. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y
Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059
[TBL] [Abstract][Full Text] [Related]
13. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
14. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
15. MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells.
Endo S; Nishimura N; Kawano Y; Ueno N; Ueno S; Tatetsu H; Komohara Y; Takeya M; Hata H; Mitsuya H; Masao M; Okuno Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):246-252. PubMed ID: 30420285
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
[TBL] [Abstract][Full Text] [Related]
17. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma.
Cloosen S; Gratama J; van Leeuwen EB; Senden-Gijsbers BL; Oving EB; von Mensdorff-Pouilly S; Tarp MA; Mandel U; Clausen H; Germeraad WT; Bos GM
Br J Haematol; 2006 Nov; 135(4):513-6. PubMed ID: 17010104
[TBL] [Abstract][Full Text] [Related]
18. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A
Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731
[TBL] [Abstract][Full Text] [Related]
19. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.
Corradini P; Voena C; Astolfi M; Ladetto M; Tarella C; Boccadoro M; Pileri A
Blood; 1995 Mar; 85(6):1596-602. PubMed ID: 7888677
[TBL] [Abstract][Full Text] [Related]
20. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
